Merus N.V. appointed Gregory D. Perry to serve as the Company's Chief Financial Officer, effective as of June 14, 2023. Additionally, Mr. Perry has been designated as the Company's principal financial officer, succeeding Sven (Bill) Ante Lundberg, M.D., in such role. In connection with his appointment as the Company's Chief Financial Officer, on June 14, 2023, Mr. Perry resigned from the Board, effective immediately prior to the Effective Time.

Gregory D. Perry, age 62, has served as a non-executive director on the Board since May 2016 and Vice Chairperson of the Board since August 2018. Mr. Perry served as the Chief Financial Officer at Finch Therapeutics Group, a microbiome therapeutics company, from May 2018 until April 2022. Mr. Perry received a B.A. in Economics and Political Science from Amherst College.